第二波新冠疫情期间抗原检测用于急性SARS-CoV-2感染诊断的建议:不同临床场景下的应用态度
本文为西班牙发布的指南文件,旨在为接诊疑似SARS-CoV-2感染患者的医生提供支持,背景为2020年9月起西班牙发病率上升、已进入第二波COVID-19疫情。文件指出SARS-CoV-2在症状出现前及出现后不久传播力高,仅诊断并隔离有症状者可能不足以阻断传播,还需保持人际距离等公共卫生措施,并需检出可占50%或以上的无症状新感染者。分子技术是诊断SARS-CoV-2感染的「金标准」,但大规模使用导致资源(分析仪、耗材和试剂)短缺和结果报告延迟,造成病例和接触者隔离措施滞后。抗原检测也是直接诊断方法,数分钟内即可在「床旁」获得结果,简单、低成本,可在某些临床场景下连续多日重复检测;其敏感性一般低于核酸检测,但特异性相当,在症状出现前后数天病毒载量较高时更为可靠。文件认为,快速实时的抗原检测比更敏感但成本更高、出结果更慢的分子检测更有助于控制感染传播。
要点
- SARS-CoV-2在症状出现前及出现后不久传播力高,仅诊断并隔离有症状者可能不足以阻断传播,还需保持人际距离等公共卫生措施。
- 无症状感染者可占50%或以上,需检出这些新感染个体。
- 分子技术是诊断SARS-CoV-2感染的「金标准」,但大规模使用导致分析仪、耗材和试剂短缺及结果报告延迟,使病例和接触者隔离措施滞后。
- 抗原检测数分钟内即可在「床旁」获得结果,简单、低成本,可在某些临床场景下连续多日重复检测;敏感性一般低于核酸检测,但特异性相当。
- 抗原检测在症状出现前后数天鼻咽病毒载量较高时更为可靠;快速实时的抗原检测比更敏感但成本更高、出结果更慢的分子检测更有助于控制传播。
适用人群与场景
- 疑似SARS-CoV-2感染的患者,适用于参与其诊治的医生。
- 文件背景为2020年9月起西班牙发病率上升、已进入第二波COVID-19疫情。
研究设计与关键结果
- 制定机构:文件未在摘要中明确列出制定机构。
- 方法:文件未在摘要中说明制定方法与证据分级体系。
- 文件指出,世界卫生组织、美国疾病控制与预防中心及西班牙卫生部提出在多种疫情防控策略中使用抗原检测。
证据类型、等级与局限
- 证据类型:指南。
- 局限:原文未报告局限性。
对床旁实践的改变
- 文件旨在支持参与诊治疑似SARS-CoV-2感染患者的医生,背景为2020年9月起西班牙发病率上升、已进入第二波COVID-19疫情。
- 文件指出,仅诊断并隔离有症状者可能不足以阻断传播,还需保持人际距离等公共卫生措施。
- 文件指出,需检出可占50%或以上的无症状新感染者。
- 文件指出,抗原检测数分钟内即可在「床旁」获得结果,简单、低成本,可在某些临床场景下连续多日重复检测。
- 文件指出,抗原检测敏感性一般低于核酸检测,但特异性相当;在症状出现前后数天鼻咽病毒载量较高时更为可靠。
- 文件认为,快速实时的抗原检测比更敏感但成本更高、出结果更慢的分子检测更有助于控制感染传播。
指南或共识出处
- 文件标题:第二波新冠疫情期间抗原检测用于急性SARS-CoV-2感染诊断的建议:不同临床场景下的应用态度。
- 发布机构:文件未在摘要中明确列出发布机构。
- 年份:文件未在摘要中明确列出年份。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The high transmissibility of SARS-CoV-2 before and shortly after the onset of symptoms suggests that only diagnosing and isolating symptomatic patients may not be sufficient to interrupt the spread of infection; therefore, public health measures such as personal distancing are also necessary. Additionally, it will be important to detect the newly infected individuals who remain asymptomatic, which may account for 50% or more of the cases. Molecular techniques are the "gold standard" for the diagnosis of SARS-CoV-2 infection. However, the massive use of these techniques has generated some problems. On the one hand, the scarcity of resources (analyzers, fungibles and reagents), and on the other the delay in the notification of results. These two facts translate into a lag in the application of isolation measures among cases and contacts, which favors the spread of the infection. Antigen detection tests are also direct diagnostic methods, with the advantage of obtaining the result in a few minutes and at the very "pointof-care". Furthermore, the simplicity and low cost of these tests allow them to be repeated on successive days in certain clinical settings. The sensitivity of antigen tests is generally lower than that of nucleic acid tests, although their specificity is comparable. Antigenic tests have been shown to be more valid in the days around the onset of symptoms, when the viral load in the nasopharynx is higher. Having a rapid and real-time viral detection assay such as the antigen test has been shown to be more useful to control the spread of the infection than more sensitive tests, but with greater cost and response time, such as in case of molecular tests. The main health institutions such as the WHO, the CDC and the Ministry of Health of the Government of Spain propose the use of antigenic tests in a wide variety of strategies to respond to the pandemic. This document aims to support physicians involved in the care of patients with suspected SC2 infection, in the context of a growing incidence in Spain since September 2020, which already represents the second pandemic wave of COVID-19.
参考来源
- Candel FJ, Barreiro P, San Román J, et al. Recommendations for use of antigenic tests in the diagnosis of acute SARS-CoV-2 infection in the second pandemic wave: attitude in different clinical settings. Rev Esp Quimioter. 2020. PMID: 33070578. doi:10.37201/req/120.2020
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。